Clinical Trial

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-23.
Status change: Recruiting → Completed 2026-03-09
Trial Details
NCT Number NCT07221084
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions Healthy Volunteers
Enrollment 21 participants
Start Date 2025-10-28
Primary Completion 2026-02-07 (estimated)
Study Completion 2026-02-27 (estimated)
Updated on ClinicalTrials.gov 2026-03-11